Kiniksa Pharmaceuticals International price to sales ratio KNSA

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 7.1×
4-year median: 5.2×
Against its 4-year history: 85th; percentile: 0 is its lowest day, 100 its highest
4-year range: 3.3× to 11.0×
Peer median: 8.5×

Kiniksa Pharmaceuticals International's price to sales ratio is 7.1× as of Oct 23, 2026.

That is above its 4-year median of 5.2×, higher than on 85% of days in the last 4 years.

Over that time it ranged from 3.3× in Apr 2025 to 11.0× in Jul 2022.

The median for 10 large drugmakers of a similar size is 8.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.1×	4.8×	7.4×
2025	5.3×	3.3×	5.5×
2024	3.8×	3.8×	5.8×
2023	5.0×	3.4×	6.2×
2022	5.9×	5.5×	11.0×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

Company	Price to sales ratio
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
ALKSAlkermes plc.	4.4×
TGTXTG Therapeutics	10.4×
INDVIndivior Pharmaceuticals	3.1×
PTGXProtagonist Therapeutics	31.8×
ARQTArcutis Biotherapeutics	8.5×
CORTCorcept Therapeutics	11.2×
LQDALiquidia	8.5×
OGNOrganon	0.6×
Peer median	8.5×

Where Kiniksa Pharmaceuticals International ranks

#93of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.